$MBX
MBX Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122840 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.865M $6.777M
YoY Change
% of Gross Profit
Research & Development $16.75M $28.53M
YoY Change 84.58%
% of Gross Profit
Depreciation & Amortization $100.0K $81.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $19.61M $35.31M
YoY Change 79.19%
Operating Profit -$19.61M
YoY Change 79.19%
Interest Expense $1.470M $2.748M
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$18.14M -$32.56M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$18.14M -$32.56M
YoY Change 78.53%
Net Earnings / Revenue
Basic Earnings Per Share -$2.78
Diluted Earnings Per Share -$2.78 -$1.02
COMMON SHARES
Basic Shares Outstanding 33.42M 6.516M
Diluted Shares Outstanding 6.516M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $277.1M
YoY Change
Cash & Equivalents $132.9M $30.52M
Short-Term Investments $144.2M
Other Short-Term Assets $838.0K $133.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $281.2M $83.47M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.033M $439.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.00K $50.00K
YoY Change
Total Long-Term Assets $1.230M $715.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $281.2M $83.47M
Total Long-Term Assets $1.230M $715.0K
Total Assets $282.4M $84.18M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.002M $1.391M
YoY Change
Accrued Expenses $5.752M $2.382M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.92M $3.926M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $112.0K
YoY Change
Total Long-Term Liabilities $112.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.92M $3.926M
Total Long-Term Liabilities $112.0K
Total Liabilities $11.03M $4.291M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$121.9M -$75.58M
YoY Change
Common Stock $393.2M $3.055M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $271.4M -$72.47M
YoY Change
Total Liabilities & Shareholders Equity $282.4M $84.18M
YoY Change

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$18.14M -$32.56M
YoY Change 78.53%
Depreciation, Depletion And Amortization $100.0K $81.00K
YoY Change 0.0%
Cash From Operating Activities -$14.66M -$18.87M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $57.00K $77.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$100.7M -$47.48M
YoY Change
Cash From Investing Activities -$100.8M -$47.56M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $68.55M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 235.8M 68.52M
YoY Change
NET CHANGE
Cash From Operating Activities -14.66M -18.87M
Cash From Investing Activities -100.8M -47.56M
Cash From Financing Activities 235.8M 68.52M
Net Change In Cash 120.4M 2.083M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$14.66M -$18.87M
Capital Expenditures $57.00K $77.00K
Free Cash Flow -$14.72M -$18.95M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001776111
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-42272
dei Entity Registrant Name
EntityRegistrantName
MBX Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1882872
dei Entity Address Address Line1
EntityAddressAddressLine1
11711 N. Meridian Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Carmel
dei Entity Address State Or Province
EntityAddressStateOrProvince
IN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
46032
dei City Area Code
CityAreaCode
317
dei Local Phone Number
LocalPhoneNumber
659-0200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MBX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33417418
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132865000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30523000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
144198000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
50153000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4107000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2789000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
281170000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
83465000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1033000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
439000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
147000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000
CY2024Q3 us-gaap Assets
Assets
282400000
CY2023Q4 us-gaap Assets
Assets
84180000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5002000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1391000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5752000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2382000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
166000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
153000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10920000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3926000
CY2024Q3 mbx Share Repurchase Liability
ShareRepurchaseLiability
68000
CY2023Q4 mbx Share Repurchase Liability
ShareRepurchaseLiability
194000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
171000
CY2024Q3 us-gaap Liabilities
Liabilities
11032000
CY2023Q4 us-gaap Liabilities
Liabilities
4291000
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
0
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
152357000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33376058
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33376058
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
237000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257080
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257080
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
393176000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3054000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121919000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75583000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
106000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
60000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
271368000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-72468000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
282400000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84180000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16747000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9073000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42192000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20807000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2865000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1872000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7392000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4513000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
19612000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10945000
us-gaap Operating Expenses
OperatingExpenses
49584000
us-gaap Operating Expenses
OperatingExpenses
25320000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19612000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10945000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49584000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25320000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1470000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
783000
us-gaap Interest And Other Income
InterestAndOtherIncome
3248000
us-gaap Interest And Other Income
InterestAndOtherIncome
1600000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18142000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10162000
us-gaap Net Income Loss
NetIncomeLoss
-46336000
us-gaap Net Income Loss
NetIncomeLoss
-23720000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
121000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
46000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
121000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
46000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
6000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18021000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10153000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46290000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23714000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18142000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10162000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46336000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23720000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.78
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.78
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.4
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.28
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6515616
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6515616
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1081349
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1081349
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3004382
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3004382
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
976824
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
976824
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-72468000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
198000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1623000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12337000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-63000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-83047000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
112000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
919000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15857000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-12000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-97885000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1192000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18142000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
121000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
271368000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-42605000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5949000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-48272000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
269000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
225000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7608000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-55390000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
595000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10162000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-64819000
us-gaap Profit Loss
ProfitLoss
-46336000
us-gaap Profit Loss
ProfitLoss
-23720000
us-gaap Share Based Compensation
ShareBasedCompensation
3734000
us-gaap Share Based Compensation
ShareBasedCompensation
1025000
mbx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
79000
mbx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
70000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1531000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
444000
us-gaap Depreciation
Depreciation
186000
us-gaap Depreciation
Depreciation
116000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1319000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-275000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3282000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
722000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3374000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1226000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-113000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-102000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38644000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20832000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
782000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
151968000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
29898000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
28000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-93250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1972000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
720000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
174542000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3735000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
mbx Payment Of Preferred Stock Issuance Costs
PaymentOfPreferredStockIssuanceCosts
279000
mbx Payment Of Preferred Stock Issuance Costs
PaymentOfPreferredStockIssuanceCosts
30000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234236000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69199000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
102342000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46395000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30523000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24210000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
132865000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70605000
mbx Vesting Of Early Exercised Stock Options And Founder Shares
VestingOfEarlyExercisedStockOptionsAndFounderShares
206000
mbx Vesting Of Early Exercised Stock Options And Founder Shares
VestingOfEarlyExercisedStockOptionsAndFounderShares
389000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
mbx Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering
215578000
mbx Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering
0
mbx Deferred Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
329000
mbx Deferred Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
mbx Proceeds From Sale Of Common Stock Convertible Preferred Stock And Convertible Notes
ProceedsFromSaleOfCommonStockConvertiblePreferredStockAndConvertibleNotes
401800000
CY2024Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
20336599
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2024Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-12.0221 reverse stock split
us-gaap Net Income Loss
NetIncomeLoss
-46300000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-32600000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121900000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
277100000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
187620000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187620000
CY2024Q3 mbx Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2411000
CY2023Q4 mbx Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2448000
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
858000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
208000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
838000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
133000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4107000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2789000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1397000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
617000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
364000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
178000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1033000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
439000
CY2024Q3 us-gaap Depreciation
Depreciation
100000
CY2023Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
100000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1850000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1365000
CY2024Q3 mbx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3717000
CY2023Q4 mbx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
903000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
185000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
114000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5752000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2382000
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
50000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
50000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
147000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
166000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
153000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
171000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
20336599
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33376058
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33376058
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257080
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257080
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0352
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0518
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0434
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2493777
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M3D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4543000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1333901
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.18
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
63194
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
198696
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.4
mbx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
3217
mbx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
3.25
mbx Share Based Compensation Arrangement By Share Based Payment Award Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchasedInPeriod
10814
mbx Share Based Compensation Arrangement By Share Based Payment Award Options Repurchased In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepurchasedInPeriodWeightedAverageExercisePrice
2.41
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3573385
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3573385
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.31
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y11M19D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
63134000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
63134000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
361000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
320000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18142000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10162000
us-gaap Net Income Loss
NetIncomeLoss
-46336000
us-gaap Net Income Loss
NetIncomeLoss
-23720000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.78
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.78
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.4
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.28
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6515616
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6515616
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1081349
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1081349
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3004382
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3004382
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
976824
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
976824
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3591424
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17750247
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-122840-index-headers.html Edgar Link pending
0000950170-24-122840-index.html Edgar Link pending
0000950170-24-122840.txt Edgar Link pending
0000950170-24-122840-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mbx-20240930.htm Edgar Link pending
mbx-20240930.xsd Edgar Link pending
mbx-ex31_1.htm Edgar Link pending
mbx-ex31_2.htm Edgar Link pending
mbx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
mbx-20240930_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable